{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-095852","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2021-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.871896+00:00","generated_at":"2026-06-30T02:31:34.748156+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Appoints Brian Strem as President & CEO; signs non-binding LOI to acquire Bayon Therapeutics","bullets":["Brian M. Strem appointed President and CEO effective July 26, 2021; Franz Obermayr returns to EVP Clinical Development.","Strem receives $400K annual base salary, target bonus of 50% of base, and option to purchase 100K shares vesting over 3 years.","EyeGate enters non-binding term sheet to acquire Bayon Therapeutics for closing consideration of 50K shares and earnout up to $7.1M or ~2.2M shares.","Strem is co-founder of Bayon and owns ~28% equity; transaction subject to definitive agreement and milestone conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-095852","json":"https://secwatch.observer/filing/0001104659-21-095852.json","markdown":"https://secwatch.observer/filing/0001104659-21-095852.md","text":"https://secwatch.observer/filing/0001104659-21-095852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/tm2123169-1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:31:34.748156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19293b7ea2","claim":"Brian M. Strem was appointed as Class I Director at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"the Board, upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the Board from seven to eight members, and appointed Dr. Strem as a Class I director to fill the resulting vacancy, in each case effective as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"6fd82189e8","claim":"Brian M. Strem was appointed as President and Chief Executive Officer at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"On July 23, 2021, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) appointed Brian M. Strem, Ph.D. as President and Chief Executive Officer of the Company, effective as of July 26, 2021 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d2fca8222d","claim":"Franz Obermayr changed role as EVP Clinical Development at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"Franz Obermayr, Ph.D., who has served as the Company’s Acting Chief Executive Officer since February 2021, resumed his prior role with the Company as its EVP Clinical Development, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resumed"},{"label":"Role","value":"EVP Clinical Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}